The global catheter-directed thrombolysis market size was valued at USD 567.92 million in 2025 and is projected to grow from USD 598.47 million in 2026 to USD 910.15 million by 2034, registering a CAGR of 5.38% during the forecast period (2026-2034). North America dominated the catheter directed thrombolysis market with a share of 40.85% in 2025.
The catheter-directed thrombolysis market includes medical devices and drug-delivery systems used to administer thrombolytic medicines directly into blood clots through a catheter. These devices are commonly classified under HSN Code 9018 (instruments and appliances used in medical or surgical sciences) and SIC Code 3841 (Surgical and Medical Instruments and Apparatus).
The catheter-directed thrombolysis market demand is driven by the need for minimally invasive treatment of blood clots and timely restoration of blood flow. Healthcare providers are using multi-side-hole infusion catheters and catheter-based thrombolytic delivery systems to deliver medication directly to clots and support targeted treatment.
Download a Free Sample To learn more about this report,
Shift toward Targeted Low Dose Thrombolytic Drug Delivery
The catheter-directed thrombolysis market analysis shows shift towards targeted low dose thrombolytic drug delivery to dissolve blood clots while limiting exposure to clot dissolving medications throughout the body. Specialized catheters deliver drugs directly into the clot, allowing clinicians to use controlled infusion protocols based on clot location, patient condition, and treatment response.
Integration of Digital Imaging with Endovascular Treatment Platforms
Integration of digital imaging is shaping the catheter directed thrombolysis market by helping clinicians visualize blood vessels, identify clot locations, and guide catheter placement during treatment. Technologies such as digital fluoroscopy, angiography, and image guided navigation provide real time anatomical information that supports procedural accuracy.
Supply chain disruptions are expected to have a high impact on the catheter directed thrombolysis market share due to dependence on specialized catheters, infusion systems, and medical-grade polymers. The market is expected to follow a stair-step recovery, as shortages of precision components, sterilization delays, and transportation constraints can affect device production. The market is expected to grow at a CAGR of 5.38%, but supply chain constraints could lower this by 0.8 percentage points, resulting in a growth of around 4.58%. As supply conditions normalize, the catheter-directed thrombolysis market growth is expected to gradually return to 5.38%.
The catheter-directed thrombolysis market forecasts strategic investment activity driven by improvements in targeted thrombolytic delivery and innovation in minimally invasive vascular interventions. In July 2026, RapidPulse closed a Series B financing of USD 48 million to advance its pulsed aspiration technology for acute ischemic stroke. The funds will support its ongoing clinical study and expansion of its catheter platform.
Demand for Minimally Invasive Blood Clot Treatment and Limb Preserving Therapies Drives Market
Demand for minimally invasive treatment of blood clots is supporting the catheter-directed thrombolysis market as healthcare providers increasingly use targeted procedures to treat conditions such as deep vein thrombosis and pulmonary embolism. Catheter-directed thrombolysis delivers clot-dissolving medication directly to the affected area, potentially reducing the need for systemic drug administration.
The need to preserve limbs in acute limb ischemia is contributing to market growth because sudden reductions in blood flow to the limbs can lead to tissue damage and potential amputation if not treated promptly. Catheter-directed thrombolysis can help dissolve obstructive blood clots and restore circulation in selected patients.
Risk of Major Bleeding Complications and Vascular Injury During Catheter Placement Restrain Market Expansion
Catheter-directed thrombolysis involves administering clot-dissolving medications directly into a blood clot, which can increase the risk of major bleeding. Patients with underlying medical conditions, recent surgery, or a history of bleeding may face additional complications during treatment. Catheter placement during thrombolysis can cause vascular injury, including damage to blood vessel walls, perforation, or local bleeding. The risk may increase when treating complex clots or navigating narrow and damaged vessels.
Expansion of Catheter-Directed Thrombolysis in Deep Vein Thrombosis Treatment and Peripheral Arterial Thrombosis Offers Growth Opportunities
Medical device manufacturers can target hospitals, vascular surgery departments, and interventional radiology centers treating selected patients with deep vein thrombosis (DVT). Revenue opportunities arise through specialized infusion catheters, drug delivery systems, procedure-specific accessories, and hospital supply agreements, contributing to catheter-directed thrombolysis market growth.
Medical device companies can target vascular specialists and hospitals managing acute limb ischemia and other serious arterial clot conditions. Improved catheter designs, precise drug delivery capabilities, and compatibility with imaging systems can help clinicians administer thrombolytic agents to targeted vessels. Revenue can be generated through advanced catheter sales, procedure kits, technology development partnerships, and distribution agreements with vascular care providers.
Catheter-directed thrombolysis is likely to witness a CAGR of 4.92%, supported by its targeted delivery of thrombolytic drugs directly to blood clots. This approach can help dissolve thrombi while limiting systemic drug exposure compared with systemic thrombolysis.
Pharmacomechanical CDT is projected to grow at a CAGR of 6.13% during the forecast period, driven by the use of combined drug delivery and mechanical clot disruption techniques.
Request Customizationto receive a tailored report.
Catheters held the leading position in the device type segment with a 42.76% share, reflecting their essential role in delivering thrombolytic agents to targeted blood clots.
Delivery systems will expand to 5.83% CAGR during the forecast period, fueled by the need for controlled administration of thrombolytic agents during procedures. These systems help clinicians manage drug delivery and maintain consistent infusion during treatment.
Deep vein thrombosis accounted for the largest share at 43.27%, owing to the use of catheter-based interventions in selected cases involving extensive venous clots and severe symptoms. Treatment aims to restore blood flow and may help reduce complications in appropriately selected patients.
Pulmonary embolism is anticipated to achieve a growth rate of 6.18% during the forecast period, driven by the need for advanced interventions in selected patients with high-risk or deteriorating pulmonary embolism.
Hospitals will achieve a growth rate of 5.1%, supported by their access to specialized interventional teams, imaging equipment, intensive care, and emergency services. These resources are important for performing catheter-directed thrombolysis and monitoring patients for complications such as bleeding.
Ambulatory surgical centers are estimated to grow at a rate of 6.19% between 2026 and 2034, supported by the expansion of outpatient endovascular services where clinically appropriate.
Speak to an Analystto discuss market opportunities.
North America's catheter-directed thrombolysis market accounted for a dominant share of 40.85% in 2025.
The American Heart Association and American College of Cardiology guidelines recognize catheter-directed thrombolysis as an option for selected patients with high-risk pulmonary embolism, particularly when advanced treatment is needed to prevent further clinical deterioration. This supports the role of catheter-based clot treatment in specialized pulmonary embolism care, alongside anticoagulation and other interventional approaches.
Canadian vascular care services use catheter-directed thrombolysis to treat selected cases of peripheral artery disease (PAD) involving acute limb ischemia, where a blood clot abruptly restricts blood flow to an extremity. Delivering thrombolytic medication directly to the clot can help restore circulation and support limb salvage when clinicians determine that the procedure is appropriate.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific catheter-directed thrombolysis market is likely to witness a CAGR of 7.13% during the forecast period, making it the fastest-growing region.
China’s stroke treatment infrastructure is expanding the use of endovascular therapy for acute ischemic stroke, including mechanical thrombectomy for eligible patients with large-vessel occlusion. Updated Chinese Stroke Association guidance addresses reperfusion treatment and the use of tissue plasminogen activator (tPA) alongside endovascular intervention, highlighting the role of catheter-based approaches in restoring blood flow and treating vascular blockages.
Japan’s National Cerebral and Cardiovascular Center provides catheter-based endovascular treatment for eligible patients with acute ischemic stroke, including those who require clot removal after intravenous tissue plasminogen activator (tPA) treatment. This integrated approach highlights the role of endovascular therapy in restoring blood flow and managing acute vascular blockages.
Kauvery Hospital in Chennai used catheter-directed thrombolysis to treat acute limb ischemia in a 93 year old patient for whom open surgery carried substantial risk. The procedure delivered clot-dissolving medication directly to the arterial blockage, demonstrating the use of minimally invasive vascular intervention to restore circulation and support limb salvage.
Europe's catheter-directed thrombolysis market is estimated to register a growth rate of 5.12% during the forecast period.
Germany’s vascular intervention services use catheter-directed thrombolysis and mechanical thrombectomy to treat selected cases of acute limb ischemia. A multicenter analysis of treatment performed in Germany reported high technical success rates for both pharmacological thrombolysis and mechanical thrombectomy.
The Royal Free Hospital in London has an established catheter-directed thrombolysis service for acute pulmonary embolism, alongside a percutaneous thrombectomy service for selected patients. This interventional approach provides alternatives for managing blood clots when treatment suitability varies, highlighting the role of catheter-based vascular procedures in specialised pulmonary embolism care.
Latin American catheter-directed thrombolysis market is expected to achieve a growth rate of 5.63% during the forecast period. Brazilian Thoracic Association addresses catheter-directed thrombolysis and catheter-based pulmonary embolectomy for selected patients with pulmonary embolism, particularly those who are unstable and cannot undergo, or do not respond to, conventional thrombolytic treatment.
In Mexico, specialized vascular care services use endovascular interventions to manage selected cases of acute arterial blockage and venous thromboembolism. Catheter-based treatment can deliver thrombolytic medication directly to a clot, complementing anticoagulation when clinically appropriate.
The Middle East & Africa catheter-directed thrombolysis market is projected to undergo growth at a CAGR of 5.47% during the forecast period. In Dubai, Al Zahra Hospital reported the treatment of a patient with a large pulmonary embolism using ultrasound-assisted catheter-directed thrombolytic therapy. The procedure delivered clot-dissolving medication directly to the blockage, illustrating how minimally invasive catheter-based treatment can help manage severe pulmonary embolism.
South Africa’s Vascular Society of Southern Africa identifies catheter-directed thrombolysis and pharmacomechanical thrombectomy as treatment options for selected cases of peripheral arterial disease. These procedures combine targeted clot-dissolving medication with catheter-based clot removal to restore blood flow.
The catheter-directed thrombolysis market competitive landscape is highly fragmented, with established medical device manufacturers and endovascular treatment specialists. Key players such as Boston Scientific, AngioDynamics, Thrombolex, Medtronic, and Edwards Lifesciences are estimated to account for 25–30% of the global catheter-directed thrombolysis market share.
Established players compete mainly through catheter design, thrombolytic drug delivery precision, and compatibility with minimally invasive vascular procedures. Emerging and regional players in the catheter-directed thrombolysis market ecosystem focus on specialized catheter technologies, improved treatment efficiency, and application-specific solutions for treating blood clots.
April 2026: Thrombolex announced enrollment of the 100th patient in its RAPID-PE clinical study evaluating the BASHIR Endovascular Catheter for intermediate-risk pulmonary embolism.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Adult Pediatric Hemoconcentrators Market Size, Opportunities, 2034
Handheld Backscatter X-Ray Devices Market Size, Share, Growth, 2034
Arterial Cannula Market Size, Forecast, Demand, Opportunities, 2034
Ultrasound Devices Market Size, Share, Growth, Analysis, 2034
Breast Biopsy Device Market Size, Forecast, Opportunities, 2034
Antimicrobial Hospital Textile Market Size, Forecast, Opportunities, 2034
We are featured on:
sales@straitsresearch.com